We are interested in buying the following list of products, in licensed bulk containers of up to the sizes noted below, to be available within a 5 year timeframe. We consider the availability in licensed bulk presentation to be a significant market advantage and are willing to consider entering contracts for supply with suppliers who can meet this presentation requirement for these products.
Estimated value in the Wales market of this list is £42,317,736.61 p/a at current prices.
The list is not exhaustive, and we are willing to consider other generic and biosimilar products if licensed bulk presentation can be offered.
Drug,Strength,Proposed Vial Size
ARSENIC TRIOXIDE,1mg/mL,
AZACITIDINE,25mg/mL,500mL
BEVACIZUMAB,25mg/mL,100mL - 250mL
BORTEZOMIB,2.5mg/mL,50mL
CALCIUM FOLINATE,10mg/mL,1000mL
CARBOPLATIN,10mg/mL,1000mL
CETUXIMAB,5mg/mL,250m – 500mL
CISPLATIN,1mg/mL,500mL - 1000mL
CYCLOPHOSPHAMIDE,20mg/mL,500mL
CYTARABINE,100mg/mL or 20mg/mL,250mL
DARATUMUMAB,20mg/mL,100mL – 250mL
DOCETAXEL,20mg/mL,250mL - 500mL
DOXORUBICIN,2mg/mL,1000mL
EPIRUBICIN,2mg/mL,1000mL
ETOPOSIDE,20mg/mL,500mL
FLUCLOXACILLIN,,3000mL
FLUOROURACIL,50mg/mL or 25mg /mL,250-500mL
INFLIXIMAB,10mg/mL,500mL - 1000mL
IRINOTECAN,20mg/mL,1000mL
NIVOLUMAB,10mg/mL,250mL
OXALIPLATIN,5mg/mL,500mL-1000mL
PACLITAXEL,6mg/mL,1000mL
PEMBROLIZUMAB,25mg/mL,100mL – 250mL
PEMETREXED,25mg/mL,100mL – 250mL
PIPERACILLIN & TAZOBACTAM,,3000mL
RITUXIMAB,10mg/mL,500mL
TOCILIZUMAB,20mg/mL,250mL
TRASTUZUMAB EMTANSINE,20mg/mL,100mL - 250mL
VEDOLIZUMAB,60mg/mL,250mL
VITLIPID N INFANT,N/A,250mL
Please inform us via the contact information above if you are able to provide these products.
Velindre NHS Trust, NHS Wales Shared Services Partnership — Procurement Services (on behalf of All Wales LHB's and Trusts)
NHS Wales Shared Services Partnership – Procurement Services (NWSSP-ProcS), hosted by Velindre NHS Trust, are seeking to go out to tender for the renewal of its All Wales Framework for the Supply of Ophthalmology Consumables CLI-OJEU-39132. In addition to the current category areas covered by this Framework Agreement, the renewal may include certain hand held/non-surgical devices used within Ophthalmology.
The Framework Agreement is and will continue to be utilised by NHS Wales Bodies as defined in the National Health Service (Wales) Act 2006.
The current Framework Agreement is broken down into Lots detailed within Section II.2 Description of this notice.
NWSSP-ProcS are looking to enter into pre-tender engagement with interested suppliers to explore all options, including amending/addition of Lots, Value-Based/Outcome-Based solutions, Social Value including Welsh Foundational Economy and Well-Being of Future Generations (Wales) Act 2015, prior to commencing the tender process. This will assist in determining the procurement route to be undertaken and inform the Lot Structure. It will also afford interested suppliers the opportunity to ask questions in an open and transparent manner.
All interested parties will be invited to an open pre-tender engagement presentation/Q&A session on Monday 17th October 2022, 10:00am-12:00noon via MS Teams. The maximum number of attendees is 40.
All interested parties are requested to express their interest in writing by email with the Subject to read “Expression of Interest” to Sheree.evans2@wales.nhs.uk.
Please include your company name, a brief overview of your Organisations activity in relation to this Tender opportunity, your contact details including your contact name, position, telephone number and contact email addresses by no later than Noon on Friday 7th October 2022.
NHS Wales Shared Service Partnership (hosted by Velindre NHS Trust)WalesWAC-298891